Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma

Ovarian clear cell carcinoma (OCCC) is an aggressive neoplasm with a high recurrence rate that frequently develops resistance to platinum-based chemotherapy. There are few prognostic biomarkers or targeted therapies exist for patients with OCCC. Here, we identified that FXYD2, the modulating subunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, I-Ling, Chou, Cheng-Yang, Wu, Yi-Ying, Wu, Jia-En, Liang, Chen-Hsien, Tsai, Yao-Tsung, Ke, Jhen-Yu, Chen, Yuh-Ling, Hsu, Keng-Fu, Hong, Tse-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325337/
https://www.ncbi.nlm.nih.gov/pubmed/26910837
http://dx.doi.org/10.18632/oncotarget.7497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325337/
https://www.ncbi.nlm.nih.gov/pubmed/26910837
http://dx.doi.org/10.18632/oncotarget.7497

Ejemplares similares